UNSPSC 51182437: Cinacalcet hydrochloride

This classification denotes a malignancy-associated hypercalcemia inhibitor with the molecular formula C22H22F3N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K860WSG25, chemically known as 1-naphthalenemethanamine, a-methyl-n-(3-(3-(trifluoromethyl)phenyl)propyl)-, (ar)-, hydrochloride but more generally known as cinacalcet hydrochloride, which bears US NIH Compound Identifier 156418.

UNSPSC 51182437 Cinacalcet hydrochloride is a Commodity code covering a specific prescription pharmaceutical used to treat hyperparathyroidism and secondary hyperparathyroidism in dialysis patients. State and local governments procure this drug through cooperative purchasing agreements and multistate pharmaceutical contracts that aggregate demand across participating agencies, including state health departments, Medicaid programs, correctional facilities, and public health systems. The work involves manufacturers and authorized wholesalers negotiating pricing, product availability, supply chain compliance, and distribution logistics to meet ongoing therapeutic needs across member jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities, including Oregon. The solicitation requires vendors to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and submit detailed pricing in flat-price, net-price, or WAC-minus formats. The contract term runs two years for new responders (with optional extensions) or aligns with existing expiration dates through June 30, 2028 for incumbents, with MMCAP reserving the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs. Evaluation weighted price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Products must be available in the marketplace by May 15, 2026 and maintain expiration dates of at least one year from manufacture with a minimum six-month shelf life.